During the past decade, Northwell Health Cancer Institute conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 3 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 3 clinical trials were completed. i.e. 37.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Northwell Health Cancer Institute" #1 sponsor was "American Society of Clinical Oncology" with 1 trials, followed by "Arcus Biosciences, Inc." with 1 trials sponsored, "Astellas Pharma Global Development, Inc." with 1 trials sponsored, "CARsgen Therapeutics Co., Ltd." with 1 trials sponsored and "Daiichi Sankyo, Inc." with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Northwell Health Cancer Institute" #1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "GOG Foundation" with 1 trials as a collaborator, "Gilead Sciences" with 1 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator and "The Americas Hepato-Pancreato-Biliary Association" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Northwell Health Cancer Institute" are "Pancreatic Cancer" (3 trials), "Acute Myeloid Leukemia (AML)" (1 trials), "Adenocarcinoma - GEJ" (1 trials), "Adenocarcinoma Gastric Stage IV With Metastases" (1 trials) and "Carcinoma, Non-Small-Cell Lung" (1 trials). Many other conditions were trialed in "Northwell Health Cancer Institute" in a lesser frequency.

Most popular intervention types in "Northwell Health Cancer Institute" are "Drug" (8 trials), "Other" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Azacitidine" (1 trials), "CT041" (1 trials), "Domvanalimab" (1 trials), "Etrumadenant" (1 trials) and "JNJ-53718678 125 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Northwell Health Cancer Institute" are 10 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Northwell Health Cancer Institute". undefined are not yet recruiting, 3 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Northwell Health Cancer Institute, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Northwell Health Cancer Institute, 2 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".